Cargando…
Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development
PURPOSE: A limit on developing new treatments for a number of central nervous system (CNS) disorders has been the inadequate understanding of the in vivo pathophysiology underlying neurological and psychiatric disorders and the lack of in vivo tools to determine brain penetrance, target engagement,...
Autores principales: | McCluskey, Stuart P., Plisson, Christophe, Rabiner, Eugenii A., Howes, Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974496/ https://www.ncbi.nlm.nih.gov/pubmed/31541283 http://dx.doi.org/10.1007/s00259-019-04488-0 |
Ejemplares similares
-
O5.5. THE NEUROBIOLOGY OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: MULTI-MODAL PET AND FMRI FINDINGS
por: Howes, Oliver, et al.
Publicado: (2020) -
Adenosine A(2A) receptor in schizophrenia: an in vivo brain PET imaging study
por: Marques, Tiago Reis, et al.
Publicado: (2021) -
The histamine system and cognitive function: An in vivo H3 receptor PET imaging study in healthy volunteers and patients with schizophrenia
por: Arumuham, Atheeshaan, et al.
Publicado: (2023) -
Reduced mu opioid receptor availability in schizophrenia revealed with [(11)C]-carfentanil positron emission tomographic Imaging
por: Ashok, Abhishekh H., et al.
Publicado: (2019) -
Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases
por: Wilson, Heather, et al.
Publicado: (2020)